Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This pre-operative window of opportunity study will use functional imaging and serological investigations to assess whether atovaquone significantly reduces tumour hypoxia in patients with non-small cell lung cancer.

STUDY DESIGN

Open label window of opportunity study

STUDY POPULATION

Patients with suspected non-small cell lung cancer (NSCLC)

PRIMARY OBJECTIVE

  • To investigate whether atovaquone reduces tumour hypoxia.

SECONDARY OBJECTIVES

  • To further investigate whether atovaquone reduces tumour hypoxia.Late SBRT toxicity (>1 month to 6 months post-surgery)
  • To determine whether atovaquone results in a change in tumour perfusion.
  • To determine whether serological markers of hypoxia may replace hyp-PET-CT imaging in future studies of hypoxia modification.
  • To determine reproducibility of hyp-PET-CT, perfusion CT, serological tests, DWI-MRI and DCE-MRI

KEY DATES

Open to recruitment: 05 May 2016

Planned accrual completion: 31 October 2018

Trial duration: 30 Months

Our team

  • Sarah Pearson

    OCTO Trial Management Director